



ASX Release

September 2016 Appendix 4C

28 October 2016, Melbourne, Australia: Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company, is pleased to provide the following Appendix 4C in relation to the quarter ended 30 September 2016.

Cash at 30 September 2016

Cash at the end of the quarter, as detailed in the attached Appendix 4C, was approximately \$9.38 million. The Company continues to manage operational expenditure carefully.

On 12 July 2016 the Company successfully placed the remaining shortfall from its Entitlement issue, raising an additional \$1.35 million. This brought the total proceeds from the Placement completed in the June 2016 quarter and Entitlement Offer to \$10.4 million, before costs.

Key activities during the quarter

During the quarter, the Company announced that the US Patent and Trademark Office (USPTO) had issued two notices of allowance under the PTX-200 patent families "Effective treatment of tumors and cancer with triciribine and related compounds" and "Compositions including triciribines and taxanes and methods of use thereof".

The first allowance bears relevance to claims involving the intravenous dosing schedule of novel Akt inhibitor, PTX-200, including a method for identifying and treating patients with tumors in the pancreas, ovary or colon that have highly expressed Akt.

The second allowance has allowed claims bearing particular relevance to PTX's ongoing breast cancer clinical trial, involving the use of PTX-200 with taxanes. These recent allowances further bolster the already broad patent portfolio for PTX-200 and its use for the treatment of tumors and cancer including novel combinations and dosing regimens. This is welcome news, especially in light of the Company's current trials in ovarian and breast cancers using PTX-200.

In September PTX presented at the 18th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & C., LLC. The conference was held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City. Mr Steven Yatomi-Clarke met with a number of investors in and around the conference, as part of the campaign to raise awareness of the Company in the US ahead of operational milestones.

On 26 September 2016, the Company announced that the H. Lee Moffitt Cancer Center (**Moffitt**) in Florida had dosed its first patient as part of the Company's Phase 1b/2 trial of its novel drug candidate PTX-200 in patients with locally advanced breast cancer.

In this trial PTX-200 is given in combination with chemotherapy agent paclitaxel as standard of care. The Phase 1b/2 trial is now in expansion phase enrollment at Albert Einstein College of Medicine and the Moffitt. The Moffitt's principal investigator on the trial is Dr Heather Han, a medical oncologist specializing in breast cancer in The Centre for Women's Oncology at the brand new, state-of-the-art McKinley Campus at the Moffitt.

Each year, the Moffitt treats over 1,000 newly diagnosed breast cancer patients, as well as hundreds more who choose the Moffitt for treatment when they have a recurrence. Whilst only a fraction of these patients will meet the strict eligibility criteria of this clinical trial, including the type of breast cancer, PTX benefits not only from the large patient population but also from the Moffitt's multidiscipline expertise in breast cancer.



The Moffitt's Comprehensive Breast Program boasts a multispecialty, full-service clinic that offers the latest in preventive care and support for all breast-related conditions. Accordingly, breast cancer patients treated at the Moffitt have survival rates above the US national average.

Proposed Issue of Loan Funded Shares

The Board of PTX agreed to issue Long Term Incentive (LTI) Shares to Mr Steven Yatomi-Clarke pursuant to his appointment as CEO and Managing Director of the Company in February this year. The Board has now agreed to increase the proposed issue of Loan Funded Shares to Mr Yatomi-Clarke a total of 8,000,000 fully paid ordinary shares, subject to meeting various vesting hurdles. This amendment is in recognition of:

1. the considerable delay in seeking approval from shareholders since Mr Yatomi-Clarke's appointment in February;
2. the performance of Mr Yatomi-Clarke since his appointment;
3. dilution following the Company's recent capital raising; and
4. amendments to the issue price of each tranche of LTI Shares that now makes them less rewarding than originally planned.

The revised terms of the proposed Loan Funded Shares are as follows:

- (a) within 5 business days of receiving all necessary approvals, the Employer will grant to the Employee a loan to the value of the 1-day VWAP per Share as at the date on which a resolution is passed for a total of 2,000,000 shares;
- (b) the loan made in accordance with paragraph (a) above:
 - (i) will be interest-free; and
 - (ii) will have an expiry date of 5 years from the grant date;
 - (iii) the loan will be repayable to the Employer at such time as the Employee sells the shares acquired, provided they are traded in accordance with the securities trading policy of the Company;

and, subject to the Employee's continuing employment with the Employer at the relevant time:

- (c) at such time on or after the date the Employer's share price reaches a 5-day VWAP of 15 cents the Employer would, at the request of the employee, grant to the Employee a loan of \$300,000 for the express purpose of acquiring 2,000,000 Shares (Tranche A);
- (d) at such time on or after the date the Employer's share price reaches a 5-day VWAP of 22 cents the Employer would, at the request of the employee, grant to the Employee a loan of \$440,000 for the express purpose of acquiring 2,000,000 Shares (Tranche B);
- (e) at such time on or after the date the Employer's share price reaches a 5-day VWAP of 29 cents the Employer would, at the request of the employee, grant to the Employee a loan of \$580,000 for the express purpose of acquiring 2,000,000 Shares (Tranche C),
- (f) any loans made in accordance with paragraphs (c) to (e) above:
 - (i) will be interest-free; and
 - (ii) the loan will be repayable to the Employer at such time as the Employee sells the shares acquired, provided:
 - A. they are traded in accordance with the securities trading policy of the Company; and
 - B. the amount due to repay the Employer shall be the lesser of each of the relevant tranches, being the market price of the initial tranche, 15 cents, 22 cents and 29 cents per Share and the amount realised on the sale of the Shares. If there is a tax liability for the Employee on repayment on the loan, in the event that the repayment is less than the advanced amount, the Employer would be responsible for payment of the tax liability incurred by the Employee.

The Company advises that approval for the above Loan Funded Shares will be included in the Company's Notice of Annual General Meeting.



About Prescient Therapeutics Limited (PTX)

PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

PTX's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials.

The first trial is a Phase Ib/II trial evaluating PTX-200 as a new therapy for relapse and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (Moffitt) and Yale Cancer Center (Yale) in New Haven, Connecticut under the leadership of Principal Investigator Professor Jeffrey Lancet, MD.


PTX is also conducting a Phase Ib/II study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt. The third trial is a Phase Ib/II trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase I trial in advanced solid tumors.

Further enquiries:

Melanie Leydin
Company Secretary
Prescient Therapeutics Limited
melanie@ptxtherapeutics.com

+61 3 9692 7222



Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

Prescient Therapeutics Limited

ABN

56 006 569 106

Quarter ended ("current quarter")

30 September 2016

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	-	-
1.2 Payments for		
(a) research and development	(276)	(276)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(335)	(335)
(f) administration and corporate costs	(403)	(403)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	14	14
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(1,000)	(1,000)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (3months) \$A'000
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	-	-

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	1,355	1,355
3.2 Proceeds from issue of convertible notes	-	-
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	(679)	(679)
3.5 Proceeds from borrowings	-	-
3.6 Repayment of borrowings	-	-
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	676	676

4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of quarter/year to date	9,753	9,753
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(1,000)	(1,000)
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4 Net cash from / (used in) financing activities (item 3.10 above)	676	676

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (3months) \$A'000
4.5	Effect of movement in exchange rates on cash held	(45)	(45)
4.6	Cash and cash equivalents at end of quarter	9,384	9,384

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	2,364	9,733
5.2	Call deposits	7,020	20
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	9,384	9,753

6.	Payments to directors of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to these parties included in item 1.2	175
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
6.3	Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2	

Payment relating to Director fees and associated on costs for the September 2016 quarter.

7.	Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1	Aggregate amount of payments to these parties included in item 1.2	-
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3	Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

N/A

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (please specify)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		


N/A

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	800
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	-
9.5 Staff costs	300
9.6 Administration and corporate costs	200
9.7 Other (provide details if material)	-
9.8 Total estimated cash outflows	1,300

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity	-	-
10.2 Place of incorporation or registration	-	-
10.3 Consideration for acquisition or disposal	-	-
10.4 Total net assets	-	-
10.5 Nature of business	-	-

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here: 
(Company Secretary)

Date: 28 October 2016

Print name: Melanie Leydin

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.